EGFR and non-small cell lung carcinoma: Many of these PTMs were up-regulated by erlotinib treatment and may provide a clue to the mechanism by which the epithelial-mesenchymal transition (EMT) facilitates acquired EGFR-TKI resistance in NSCLC [58].